Brief: Appili Therapeutics Completes Enrollment For COVID-19 Viral Shedding Sub-Study
17/09/2021 12:25
Sept 17 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT
ENROLLMENT
FOR AVIGAN®/REEQONUS™ VIRAL SHEDDING SUB- STUDY FOR
MILD-TO-MODERATE COVID-19 PATIENTS
* APPILI THERAPEUTICS - VIRAL SHEDDING SUB-STUDY RESULTS ARE
EXPECTED CONCURRENTLY WITH PRESECO TOP-LINE RESULTS
Source text for Eikon: ID:nBw70zgPVa
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez